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Oral Presentations 7dose is critical for UCBT. Previously mortality risks outweigh ben-
efits in using UCBT for thalassemia.With strategies that maximize
cell dose – using non-red cell reduced but plasma depleted (PD)CB,
no post-thawwash (NW), and double cord transplantation (DCT) –
promising results may be achieved with UCBT in young thalasse-
mics. Between 7/2001 and 1/2006, 63 CB products were infused af-
ter Bu/Cy/ATG myeloablation in 51 pediatric thalassemia major
patients (11 DCT & 1 re-transplant) at 14 transplant centers
(TC) using 82% PD CB with 92% NW. Patient status: 20 Pesaro
class 1, 11 class 2, 1 class 3, and 19 status unknown. Median age
was 4.3 years (range 0.3–20 years) with a median weight of 17 kg
(range 4–45 kg). The data was audited by TC, NMDP and on-
site by CIBMTR with 97.3% accuracy. No significant adverse
events were observed despite major ABO incompatibility in some
cases and NW. Cumulative incidence estimates of neutrophil
(ANC500), platelet 20K and platelet 50K (plt 20 & 50K) engraft-
ment with donor chimerism were 86 6 8%, 74 6 9% and 74 6
9%, and median times to ANC500, plt 20K and 50K engraftment
were 17 days (range 11–32), 40 days (range 16–135) and 60 days
(range 30–144) after transplantation respectively. 7 patients died in-
cluding 2 deaths prior to day 20 and one due to traumatic head in-
jury. 42 patients engrafted, 9 with autologous recovery, and 38
patients are alive with a mean and median follow up time of 537
and 296 days respectively (range 8–2,691 days) as of May 2007. Re-
sults appear to show improvement with TC experience TC (.5
cases of UCBT for thalassemia) and NW. Patients receiving PD
versus red cell depletion (RCD) CB were compared by matched-
pair analyses where patients were matched by TC experience,
wash status, age, weight, TNC dose, and #HLA matches (Paired
Prentice-Wilcoxon Test). The results (table) showed fewer autolo-
gous recovery (p5 0.04) and better thalassemia-free survival (DFS;
p5 0.01) for PD compared to RCD patients. Overall survival (OS)
and transplant-related mortality (TRM) also trended in favor of PD
patients (both p5 0.08). To our knowledge, this is the largestmulti-
institutional UCBT series for thalassemia and demonstrate that at
experienced TC, 93 6 6% ANC engraftment and 88 6 8% 1-
year DFS are attainable, when cell dose is optimized with PD
CBU, no post-thaw wash and DBT when necessary.
Autologous
ANC500 Plt 50 K Recovery TRM OS DFSP-value NS NS 0.04 0.08 0.08 0.01
In favor of PD PD PD PDNS 5 Not Significant.
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THE OUTCOME OF ALLOGENEIC STEM CELL TRANSPLANTATION
(AlloSCT) FOR THE TREATMENT OF THERAPY-RELATED MYELODYS-
PLASTIC SYNDROME (tMDS) AND ACUTE MYELOID LEUKEMIA (tAML)
VARIES CONSIDERABLY BY RISK FACTOR: AN OBSERVATIONAL STUDY
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TRANSPLANT RESEARCH (CIBMTR)
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We report outcomes of alloSCT for tMDS and tAML in 868 sub-
jects transplanted between 1990 and 2004 at 211 centers in 33 coun-
tries. 21% were#19 years old (yo); 55% were female and 63% had
tAML (including 30% with prior tMDS). Prior treatment was che-
motherapy in 43%, chemotherapy and radiation therapy in 51%
and radiation therapy alone in 4%. Prior diagnoses included Hodg-
kin lymphoma (23%) and non-Hodgkin lymphoma (21%), breast
cancer (16%), ALL (12%), sarcoma (8%), germ cell tumor (6%),
and autoimmune disorders (5%). Cytogenetic data (cd) at the
time of transplant were known in 84%: good prognosis 4%, inter-
mediate 61% and poor 34%. The IPSS score at diagnosis for sub-jects with tMDS was intermediate-2 or high in 54%. At
transplant, 51% of subjects with tAMLwere in first complete remis-
sion (CR1), 7% $ CR2, 15% in relapse and 27% were primary in-
duction failures. For the tMDS pts, 37% had been treated with
other modalities before receiving an alloSCT. Pre-transplant con-
ditioning regimen was myeloablative (M) 77% and reduced inten-
sity (RI or non-M) in the remainder. Donors were related 38%
and unrelated 62%; 66% of the grafts were bone marrow and
34% peripheral blood stem cells. Cumulative incidence of acute
GVHD (grade II-IV) @100 days was 39% (95% confidence interval
[CI]), 35–42). Outcomes, with a median follow-up of 61 (range, 3–
187) months were: In multivariate analysis (MVA), DFS and OS
were lower in subjects .35 yo, with poor prognosis cd, AML not
in CR or untreatedMDS, or with amismatched related or unrelated
donor. The use of a RI or non-M conditioning regimen did not im-
prove outcomes in the MVA. Survival was significantly better in pts
\35 yo, with good or intermediate risk cd, disease control at the
time of transplant and having a matched related or complete or par-
tially matched-unrelated donor. The 5 year survival was 50% (95%
CI, 39–61) with all 4 good risk factors (grf); 25% (95% CI, 20–31)
with any 3 grf, 19% (95% CI, 14–24) with any 2 grf, 12% (95% CI,
8–18) with only 1 grf, and only 4% (95% CI, 0–15) without any of
these factors. In conclusion, easily identifiable risk factors predict
outcome after alloSCT for tMDS and tAML.
5 year probability
Outcome: (95% CI)Chronic GVHD 30 (27–33)
Treatment-related mortality (TRM) 48 (44–51)
Relapse 31 (28–34)
Disease-free survival (DFS) 21 (18–24)
Overall survival (OS) 22 (19–26)14
UNRELATED CORD BLOOD TRANSPLANTATION AFTERMYELOABLATIVE
CONDITIONING IN 98 ADULT PATIENTSWITH ACUTE LEUKEMIA: A SIN-
GLE-INSTITUTE EXPERIENCE IN JAPAN
Ooi, J., Takahashi, S., Tomonari, A., Tsukada, N., Konuma, T.,
Kato, S., Kasahara, S., Tojo, A., Asano, S. Institute of Medical Science,
University of Tokyo, Tokyo, Japan.
We analyzed outcomes and risk factors after unrelated cord blood
transplantation (CBT) for 98 adult patients with acute leukemia.
Between August 1998 and June 2007, 98 adult patients with acute
leukemia were treated with unrelated CBT at The Institute ofMed-
ical Science, University of Tokyo. Diagnoses at transplantation in-
cluded de novo AML (n 5 55), ALL (n 5 25), and MDS-related
secondary AML (n 5 18). 59 (60%) patients were transplanted in
an advanced status of the disease (defined as acute leukemia in third
or subsequent complete remission, not in remission, or with high-
risk cytogenetics). All patients received four fractionated 12Gy total
body irradiation and chemotherapy as myeloablative conditioning.
95 patients received standard cyclosporine (CyA) and methotrexate,
and 3 patients received CyA only as a graft-versus-host disease
(GVHD) prophylaxis. Among the patients the median age was 40
years (range, 18–55 years), the median weight was 56 kg (range,
36–76 kg), the median number of cryopreserved nucleated cells
was 2.46  10 7/kg (range, 1.16–5.29  10 7/kg) and the median
number of cryopreserved CD34 positive cells was 0.93  10 5/kg
(range, 0.15–8.97 10 5/kg). 92 patients hadmyeloid reconstitution
and the median time to more than 0.5 10 9/L absolute neutrophil
count was 21 days. A higher CD34 positive cell count was indepen-
dently associated with faster neutrophil recovery (p 5 0.0001). A
self-sustained platelet count more than 50  10 9/L was achieved
in 86 patients at a median time of 42 days. Acute GVHD greater
than or equal to grade III occurred in 6 of 92 evaluable patients
and chronic GVHDoccurred in 67 of 84 evaluable patients. Among
67 chronic GVHD patients, 19 patients were extensive type. 69 pa-
tients are alive and free of disease at between 116 and 3322 days after
CBT.With a median follow-up of 1677 days, the probability of dis-
ease-free survival (DFS) at 5 years was 68.5 6 5%. The 5-year
